Condition: Non Small Cell Lung Cancer · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.
This description comes directly from the study's public registry record.
zhang zhenfeng, MD,PHD · 02034153532 · zhangzhf@gzhmu.edu.cn
CHEN deji, MD,PHD · 02034153532 · chendeji2003@163.com
Always discuss trial participation with your own doctor first.
| zhang Zhenfeng | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03769129